Immunology 2022

Poster Session Poster number: P620 Title: RenMice™ HiTS Platform Enables Identification of Novel Therapeutic Antibodies Date: Sunday, May 8, 2022 Time: 2:30 PM - 3:45 PM…

Read more
Biocytogen Enters into Antibody Agreement with Merck

BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck…

Read more
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully…

Read more
Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers

BEIJING and SHANGHAI, April 18, 2022/PRNewswire/--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced a collaboration agreement with CtM Biotech (Shanghai) Co., Ltd…

Read more
Biocytogen Subsidiary Eucure Biopharma Completes First Patient Dosing for Phase I Clinical Trial of YH003 (Anti-CD40 mAb) Triple Combination Therapy

BEIJING, April 6, 2022 - Biocytogen subsidiary Eucure Biopharma announced the first patient dosing for a phase I clinical trial (No. YH003005) of YH003 (anti-CD40…

Read more
Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany

Beijing, China and Heidelberg, Germany, March 28, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as “Biocytogen”) announced the opening of the Biocytogen…

Read more
Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia

BEIJING, CHINA, March 8, 2022 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial…

Read more
Webinar: Mouse Models to Investigate New Treatments for Inflammatory Disease

We’re pleased to continue our new webinar series informing and updating our network of research professionals. We invite you to join us to learn about…

Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia

Beijing, China, December 9, 2021/PRNewswire/ – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial…

Read more
2021 Highlights: Humanized Model Publications

We are proud to highlight our growing list of publications featuring off-the-shelf and customized mouse, rat, and cancer cell models in well-respected, high-impact journals. Featured below…

Read more
Back to top